CBD – What Is It And What Does It Do?
This scientific study was written by David Heal PhD, DSc, FRSC, FBPhS, co-founder and Executive Director of DevelRx.
EthicaCBD want to be a company you know you can trust. Quality and safety are our primary ethical goals as well as transparency and provision of accurate information about our products. We also aim to be a valuable resource of information about CBD and other cannabinoids. In order to assist with these objectives, we are delighted to be working with DevelRx, a scientific team with decades of relevant scientific experience.
With over 30 years experience, 12 successful drug registrations and over 100 companies supported, DevelRx are experts in their fields. Meet the team and read their synopsis of the work they have carried out with EthicaCBD.
David Heal PhD, DSc, FRSC, FBPhS is a co-founder and Executive Director of DevelRx. His early training included 12 years in academic research in the Department of Clinical Pharmacology at the University of Oxford. In 1998, he was awarded a higher doctorate by Kings College, University of London for his outstanding contribution to research on brain disorders and their treatment. He is currently Visiting Professor in Pharmacy and Pharmacology at the University of Bath.
Sharon Smith, Jane Gosden and David Heal make up the team at DevelRx, each with more than 25 years of experience in senior roles in pharmaceutical R&D. DevelRx specializes in the efficacy and safety evaluation of drugs to treat psychiatric and neurological disorders and has contributed significantly to the registration of 15 new drugs. DevelRx’s scientific team also played a major role in the safety evaluation of cannabidiol as an epilepsy treatment and are internationally recognized experts in the area of cannabinoids.
Recently, DevelRx have investigated the structure and purity of EthicaCBD products and reviewed the scientific data regarding their proposed use, in support of their novel foods dossier. Further, it has agreed to provide medical and scientific education because of EthicaCBD’s ethical approach to the use of cannabidiol as a novel food and the critical need to provide the public with sound and unbiased information about cannabidiol and other cannabinoids.
DevelRx has built an international reputation for scientific independence and expertise. DevelRx is pleased to have been invited to act as a scientific advisor for EthicaCBD and looks forward to the opportunity of providing insights into CBD and cannabinoids, which is an area of special scientific interest.
This scientific study was written by David Heal PhD, DSc, FRSC, FBPhS, co-founder and Executive Director of DevelRx.
EthicaCBD want to be a company you know you can trust. The scientists at DevelRx (experts in drug development who support the Pharmaceutical and Biotech
A landmark study in 2020 revealed that CBD does not impair driving. This was pivotal because past studies had only looked at the effects of cannabis and
This scientific study was written by David Heal PhD, DSc, FRSC, FBPhS, co-founder and Executive Director of DevelRx. Find out more about our team of
This scientific study was written by David Heal PhD, DSc, FRSC, FBPhS, co-founder and Executive Director of DevelRx. Find out more about our team of
EthicaCBD, Unit 7 Bude Business Centre, Kings Hill Industrial Estate, Bude, Cornwall, UK, EX238QN.